RYTM
Rhythm Pharmaceuticals, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 112 | +7 | 44.38M | $4.90B | +14 | −8 |
| Q1 2026 | 109 | +6 | 41.83M | $3.64B | +11 | −6 |
| Q4 2025 | 102 | 0 | 43.14M | $4.62B | +3 | −2 |
| Q3 2025 | 20 | +1 | 28.88M | $2.92B | +2 | −2 |
| Q2 2025 | 17 | 0 | 22.96M | $1.45B | +1 | −1 |
| Q1 2025 | 14 | +2 | 11.52M | $610.22M | +2 | — |
| Q4 2024 | 12 | 0 | 11.40M | $638.39M | — | — |
| Q3 2024 | 11 | +3 | 9.71M | $508.75M | +3 | — |
| Q2 2024 | 8 | — | 9.56M | $392.54M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | PRIMECAP Management ✦ | 7.31M | — | $300.25M | 0.2% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.25M | — | $51.45M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | T. Rowe Price ✦ | 525.94K | — | $21.60M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Wellington Management ✦ | 202.33K | — | $8.31M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 5 | Marshall Wace ✦ | 106.81K | — | $4.39M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 103.83K | — | $4.26M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 7 | Norges Bank ✦ (passive) | 43.24K | — | $1.78M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Gotham Asset Management ✦ | 12.63K | — | $518,465 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 284 holders, 72.02M shares, $6.12B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 1.82K sh · $189,965
Officer, Director · 8.70K sh · $899,634
Officer, Director · 30.75K sh · $3.15M
Officer, Director · 6.44K sh · $655,145
Officer, Director · 2.30K sh · $241,937
Officer · 11.51K sh · $1.21M
Officer · 23.07K sh · $2.41M
Officer · 28.19K sh · $2.99M
Officer · 2.01K sh · $233,031
Officer · 1.56K sh · $182,170
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology